Author/Authors :
Mohammadi, Mehrdad Department of Microbiology and Immunology - Faculty of Medicine - Kashan University of Medical Sciences - Kashan - Iran , Sandle, Tim Bio Products Laboratory - Elstree - Hertfordshire - United Kingdom , Rajabi, Sajad Department of Gynecology and Obstetrics - School of Medicine - Iran University of Medical Sciences - Tehran - Iran , Khorshidi, Ahmad Department of Microbiology and Immunology - Faculty of Medicine - Kashan University of Medical Sciences - Kashan - Iran , Piroozmand, Ahmad Department of Microbiology and Immunology - School of Medicine - Kashan University of Medical Sciences - Kashan - Iran
Abstract :
The novel Coronavirus Disease 2019 (COVID-19) appeared as an emerging respiratory disease in December 2019 in Wuhan, Hubei province, China, and then spread rapidly worldwide, being declared a pandemic on March 11, 2020. Researchers are attempting to discover specifically designed antiviral treatments for COVID-19. Several therapeutic agents such as Interferon-α, Lopinavir/Ritonavir, Ribavirin, Chloroquine, Chloroquine phosphate, Hydroxychloroquine, Arbidol, Favipiravir, Remdesivir, Darunavir, Imatinib, Teicoplanin, Azithromycin, COVID-19 convalescent plasma, other potential antiviral drugs, and Chinese herbal agents are now being clinically studied to examine both pharmaceutical efficacy and safety for COVID-19 treatment in several countries. Some favorable results from these studies have been obtained to date. This review article summarizes and reiterates drugs that are potentially efficient against COVID-19
Keywords :
Novel Coronavirus , COVID-19 , Antiviral Drug , Treatment
